ArticleBiomaterials research2026
Targeted Sirtuin 3 Activation by Biomimetic Black Phosphorus Nanosheets Mitigates Sepsis-Induced Acute Kidney Injury through Yeast Mitochondrial Escape 1-Like 1 Deacetylation.
Article in Biomaterials research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis-induced acute kidney injury (AKI) is characterized by mitochondrial dysfunction and dysregulated inflammation, with a lack of effective therapies. Studies have found that down-regulation of Sirtuin 3 (Sirt3) expression in renal tubular epithelial cells is associated with mitochondrial imbalance, suggesting its potential as a therapeutic target. Based on this, the research team developed a targeted nanodelivery system: black phosphorus nanosheets loaded with a cortistatin agonist were encapsulated with macrophage membranes modified with (KKEEE)₃K peptides to specifically deliver Sirt3-activating components to the kidneys. This nanosystem demonstrated favorable stability and biocompatibility. Ex vivo experiments confirmed its ability to alleviate lipopolysaccharide-induced oxidative stress, apoptosis, and inflammation in HK-2 cells, while restoring mitochondrial function. Mechanistically, the nanomaterial regulates mitochondrial homeostasis by activating the Sirt3-YME1L1 deacetylation axis. This study provides a novel nano-therapeutic strategy for sepsis-induced AKI, combining targeting capability with metabolism regulation, and holds broad implications for the treatment of inflammatory organ damage.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.